Pharma Stocks Soar Amid Mega Deal Speculation
The recent merger speculation surrounding AstraZeneca and Bristol Myers Squibb has caused large-cap pharma stocks to surge in value. Stocks such as Eli Lilly, Johnson & Johnson, and GSK have seen significant price movements due to the potential mega-deals.
Eli Lilly stands out with its scale, broad vaccine and specialty medicine portfolio, and active oncology pipeline at a P/E of 16x, which is well below many peers. The company has over 20 Phase III starts in 2026 and a new £400m Cambridge research hub, while also targeting £1.9b in cost savings to support margins.
However, investors need to weigh legal overhangs from Zantac, patent expiries, and a high debt load that has already fed into EPS guidance cuts after the Nuvalent deal. Eli Lilly is a central player in the GLP 1 obesity and diabetes theme with products such as Mounjaro and Zepbound supported by long patent protection.
The company is committing large sums to new plants and earlier stage deals across radiopharmaceuticals, neuroscience, and AI-driven drug discovery. Earnings growth forecasts are in the mid-teens, and strong margins indicate that investors already place a high value on this pipeline.